新版医保目录实施后，多款创新药开出“医保首方”，患者用药门槛降低

Core Viewpoint - The implementation of the new National Medical Insurance Drug List and the Commercial Insurance Innovative Drug List on January 1, 2026, marks a significant enhancement in drug accessibility for patients, with 114 new drugs added to the national list and 19 to the commercial list, optimizing medication security for the public [1][3][4]. Summary by Sections National Medical Insurance Drug List - The new National Medical Insurance Drug List includes 114 new drugs, with 50 classified as innovative drugs, representing the highest number and proportion of innovative drugs added in history [4][15]. - The newly added drugs aim to fill clinical treatment gaps, offer superior alternatives, or provide better cost-effectiveness, particularly enhancing coverage for cancer, chronic diseases, mental health, rare diseases, and pediatric medications [4][15]. Commercial Insurance Innovative Drug List - The first version of the Commercial Insurance Innovative Drug List includes 19 drugs, focusing on high innovation, significant clinical value, and patient benefits that exceed basic insurance coverage [5][16]. - The list features treatments for conditions such as cancer (e.g., CAR-T therapies), rare diseases (e.g., neuroblastoma, Gaucher disease), and Alzheimer's disease, reflecting a commitment to support innovative therapies [5][16]. Implementation and Accessibility - As of January 20, 2026, 99 new drugs from the basic medical insurance list are available in 12,198 designated medical institutions, while 14 drugs from the commercial list are available in 223 institutions [7][19]. - Local medical insurance departments are actively ensuring the supply and settlement of new drugs, with measures such as updating drug databases and holding specialized drug meetings to facilitate the integration of new drugs into hospital procurement lists [19][20]. Public Access and Information - The public can access information about the drugs included in the new lists through the "National Medical Insurance Bureau" WeChat account, allowing users to search for drug names and check their status in the directories [17]. Future Directions - The implementation of the dual directories (national and commercial) is expected to enhance the efficiency of medical insurance fund usage and improve public medication security, with ongoing adjustments to ensure that essential and effective new drugs are included while removing outdated ones [11][24][25].